Pharmaceutical Commerce

FEBRUARY 21, 2024

Regeneron Pharmaceuticals’ linvoseltamab is currently in clinical development to treat adult patients with relapsed/refractory multiple myeloma who experienced disease progression following prior administration of at least three therapies.

FDA 59

FDA Pharmaceutical Patients 59

Pharmaceutical Technology

FEBRUARY 8, 2024

GEN-3014 is under clinical development by Genmab and currently in Phase II for Relapsed Multiple Myeloma.

75

75

Pharmacy Times

NOVEMBER 20, 2023

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

Patients 49

Patients 49

MedCity News

DECEMBER 9, 2022

In partnering with clinical-stage Arcellx, Gilead Sciences gains the opportunity to develop a cell therapy for multiple myeloma that could offer advantages over currently available therapies for the blood cancer.

Biopharma 114

Biopharma Pharma 114

European Pharmaceutical Review

JANUARY 19, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Ninlaro ® (ixazomib) with lenalidomide and dexamethasone for treating relapsed/refractory multiple myeloma (RRMM). It was the first oral proteasome inhibitor to enter Phase III clinical trials and to receive a regulatory approval.

Consulting 76

Consulting Safety Patients Pharmaceutical 76

pharmaphorum

NOVEMBER 22, 2022

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market. Some patients will be able to continue to receive the drug via a compassionate use programme.

Marketing 105

Marketing FDA Patients Safety 105

Pharmaceutical Technology

APRIL 24, 2023

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending the use of Darzalex (daratumumab) with bortezomib and dexamethasone (DVd) for adults with previously treated multiple myeloma. Myeloma is a treatable but incurable type of bone marrow cancer.

Management 98

Management Patients 98

Pharmacy Times

JANUARY 22, 2024

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Management 48

Management 48

Pharmacy Times

FEBRUARY 22, 2024

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Patients 49

Patients Safety FDA 49

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Additionally, Kite will make other potential payments to Arcellx.

Manufacturing 105

Manufacturing Marketing Pharmaceutical Patients 105

Pharmaceutical Technology

OCTOBER 27, 2023

Eftozanermin alfa is under clinical development by AbbVie and currently in Phase I for Refractory Multiple Myeloma.

52

52

Pharmaceutical Technology

FEBRUARY 7, 2024

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma.

40

40

European Pharmaceutical Review

NOVEMBER 7, 2022

has announced its B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb) elranatamab for relapsed or refractory multiple myeloma (RRMM) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA). Elranatamab clinical trial data. Pfizer Inc. The majority were either Grade 1 (43.2

Food and Drug Administration 97

Food and Drug Administration Medicine Safety FDA 97

Pharmacy Times

DECEMBER 9, 2023

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

Patients 29

Patients 29

Pharmaceutical Technology

NOVEMBER 14, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Pepaxti provides clinical benefit to patients with triple class refractory disease.

Marketing 52

Marketing Patients Medicine Healthcare 52

Pharmaceutical Technology

FEBRUARY 8, 2024

GEN-3014 is under clinical development by Genmab and currently in Phase II for Refractory Multiple Myeloma.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

JANUARY 8, 2024

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

DECEMBER 21, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma.

40

40

European Pharmaceutical Review

NOVEMBER 7, 2022

The findings will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T.”. “The The findings will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T.”.

Prospecting 77

Prospecting Physicians Patients Medicine 77

Pharmaceutical Technology

SEPTEMBER 14, 2023

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma.

40

40

Pharmaceutical Technology

SEPTEMBER 14, 2023

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Relapsed Multiple Myeloma.

40

40

Pharmaceutical Technology

OCTOBER 27, 2023

Eftozanermin alfa is under clinical development by AbbVie and currently in Phase I for Relapsed Multiple Myeloma.

52

52

pharmaphorum

JANUARY 29, 2023

One of the Johnson & Johnson’s top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti. The post Trial sets up earlier use of J&J’s Carvykti in myeloma appeared first on.

Sales 64

Sales Prospecting Patients Manufacturing 64

European Pharmaceutical Review

MARCH 6, 2024

The FDA noted that its decision for the biosimilars is based on clinical study data, which showed no clinically meaningful differences from the reference medicines. Wyost Similarly, Wyost 120 mg/1.7 mL (70 mg/mL) injection is a human monoclonal antibody designed to bind to the RANKL protein.

Food and Drug Administration 92

Food and Drug Administration Medicine FDA Food 92

Pharmacy Times

JULY 21, 2023

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.

Patients 49

Patients 49

Pharmaceutical Technology

OCTOBER 26, 2022

The US Food and Drug Administration (FDA) has granted approval for the Janssen Pharmaceutical Companies of Johnson & Johnson ’s (J&J) Tecvayli (teclistamab-cqyv) to treat relapsed or refractory multiple myeloma in adults. It is the fourth treatment for multiple myeloma for Janssen to obtain approval.

Food and Drug Administration 52

Food and Drug Administration FDA Physicians Food 52

pharmaphorum

DECEMBER 12, 2022

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetamab candidate should be viewed as an important new option for the blood cancer. mg/kg dose and 73% at a 0.8

Side effects 52

Side effects Patients Marketing 52

European Pharmaceutical Review

FEBRUARY 1, 2024

In this initial clinical study of the BCMA CAR T therapy, investigators evaluated the safety and efficacy of Equecabtagene Autoleucel infusion in relapsed/refractory antibody-mediated idiopathic inflammatory diseases of the nervous system. Only transient hemocytopenia was observed.

Safety 85

Safety Patients Medical Pharmaceutical 85

pharmaphorum

AUGUST 11, 2022

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial. Once considered a niche by skeptics, CAR-T is taking on standard of care in multiple cancers and beating it.

Safety 52

Safety FDA Food Patients 52

Pharmaceutical Technology

MARCH 1, 2023

Orvacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Retail 40

Retail Distribution Government Medicine 40

European Pharmaceutical Review

JULY 26, 2022

Amvuttra * (vutrisiran) was recommended for marketing authorisation as a treatment for adults with hereditary transthyretin-mediated amyloidosis, a rare life-threatening disease that damages multiple nerves across the body. Hybrid medicine Thalidomide Lipomed (thalidomide) received a positive opinion for the treatment of multiple myeloma.

Medicine 90

Medicine Marketing Patients Safety 90

pharmaphorum

AUGUST 19, 2022

The European Commission has approved Oncopeptides’ Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words those who don’t respond to all three of the major classes of treatment for the blood cancer.

FDA 52

FDA Safety Sales Marketing 52

Pharmacy Times

OCTOBER 20, 2022

Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.

Patients 49

Patients Management 49

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer. In the MagnetisMM-3 trial, elranatamab was associated with an ORR of 60.6%

Medicine 52

Medicine FDA Recruitment Patients 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. EU and Asia.

Retail 45

Retail Manufacturing Government Pharmaceutical 45

pharmaphorum

DECEMBER 23, 2022

Here, Richard Staines reports on phase I/II data unveiled at the American Society of Hematology conference that supports further clinical development of inobrodib in multiple myeloma and other blood cancers. Results suggest durable epigenetic re-wiring and provide rationale for intermittent clinical dosing.

Side effects 52

Side effects Patients Medical Medicine 52